Relevance of the gut/joint axis for the management of spondyloarthritis in daily clinical practice

Current Opinion in Rheumatology

Volumn 26, Issue 4, 2014, Pages 371-376

  Cypers, Heleen ^a   Van Praet, Liesbet ^a   Varkas, Gaëlle ^a   Elewaut, Dirk ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

microscopic gut inflammation; risk stratification; spondyloarthritis; therapeutic implications

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROBIOTIC AGENT; RITUXIMAB; SECUKINUMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB;

ANKYLOSING SPONDYLITIS; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BONE MARROW EDEMA; CELIAC DISEASE; CLINICAL PRACTICE; CROHN DISEASE; DISEASE ACTIVITY; ENTERITIS; HUMAN; INTESTINE; INTESTINE FLORA; LACTOBACILLUS CASEI; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; PSORIASIS; REVIEW; RISK ASSESSMENT; SPONDYLARTHRITIS; ULCERATIVE COLITIS;

EID: 84901834415     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000070     Document Type: Review

References (47)

1. Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of Spondylo-Arthritis International Society (ASAS) handbook: a guide to assess spondylo-arthritis. Ann Rheum Dis 2009; 68:1-44.
2. De Vos M, Mielants H, Cuvelier C, et al. Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology 1996; 110:1696-1703. (Pubitemid 26169205)
3. Rahman P, Inman RD, Gladman DD, et al. Association of interleukin-23 receptor variants with ankylosing spondylitis. Arthritis Rheum 2008; 58:1020-1025. (Pubitemid 351564003)
4. Cortes A, Hadler J, Pointon JP, et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nature Genet 2013; 45:730-740.
5. Scher JU, Sczesnak A, Longman RS, et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. eLife 2013; 2:e01202.
6. Taurog JD, Richardson JA, Croft JT, et al. The germ-free state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994; 180:2359-2364. (Pubitemid 24351619)
7. Dieleman LA, Goerres MS, Arends A, et al. Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut 2003; 52:370-376. (Pubitemid 36250056)
8. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464:59-65.
9. Packey CD, Sartor RB. Commensal bacteria, traditional and opportunistic pathogens, dysbiosis and bacterial killing in inflammatory bowel diseases. Curr Opin Infect Dis 2009; 22:292-301.
10. Laukens D, Peeters H, Marichal D, et al. CARD15 gene polymorphisms in patients with spondyloarthropathies identify a specific phenotype previously related to Crohn's disease. Ann Rheum Dis 2005; 64:930-935. (Pubitemid 40733921)
11. Jenks K, Stebbings S, Burton J, et al. Probiotic therapy for the treatment of spondyloarthritis: a randomized controlled trial. J Rheumatol 2010; 37:2118-2125.
12. Shen J, Zuo ZX, Mao AP. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials. Inflamm Bowel Dis 2014; 20:21-35.
13. Vaghef-Mehrabany E, Alipour B, Homayouni-Rad A, et al. Probiotic supple-mentation improves inflammatory status in patients with rheumatoid arthritis. Nutrition 2014; 30:430-435.
14. Van Praet L, Van den Bosch FE, Jacques P, et al. Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis 2013; 72:414-417.
15. Van Praet L, Jans L, Carron P, et al. Degree of bone marrow oedema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: results from the GIANT cohort. Ann Rheum Dis 2013; 10.1136/annrheumdis-2013-203854. [Epub ahead of print]
16. Van der Heijde D, Landewe R, Baraliakos X, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondy-litis. Arthritis Rheum 2008; 58:3063-3070.
17. Van der Heijde D, Landewe R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008; 58:1324-1331. (Pubitemid 351705922)
18. Van der Heijde D, Salonen D, Weissman BN, et al. Assessment of radio-graphic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009; 11:R127. (This article is online at: http://arthritis-research.com/content/11/4/R127).
19. Maksymowych WP, Morency N, Conner-Spady B, Lambert RG. Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification. Ann Rheum Dis 2013; 72:23-28.
20. Baraliakos X, Haibel H, Listing J, et al. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis 2014; 73:710-715.
21. Haroon N, Inman RD, Learch TJ, et al. The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 2013; 65:2645-2654.
22. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371:660-667. (Pubitemid 351284485)
23. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenter-ology 2010; 138:463-468.
24. Her M, Kavanaugh A. Treatment of spondyloarthropathy: the potential for agents other than TNF inhibitors. Curr Opin Rheumatol 2013; 25:455-459.
25. Kroon F, Landewe R, Dougados M, van der Heijde D. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis 2012; 71:1623-1629.
26. Higuchi K, Umegaki E, Watanabe T, et al. Present status and strategy of NSAIDs-induced small bowel injury. J Gastroenterol 2009; 44:879-888.
27. Feagins LA, Cryer BL. Do nonsteroidal anti-inflammatory drugs cause exacerbations of inflammatory bowel disease? Digest Dis Sci 2010; 55:226-232.
28. El Miedany Y, Youssef S, Ahmed I, El Gaafary M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective Cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol 2006; 101:311-317. (Pubitemid 43381673)
29. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010; 4:28-62.
30. Song IH, Rudwaleit M. Certolizumab pegol in axial spondyloarthritis. Exp Rev Clin Immunol 2013; 9:1161-1172.
31. Kirkham BW, Kavanaugh A, Reich K. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology 2014; 141:133-142.
32. Ciccia F, Bombardieri M, Principato A, et al. Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subdinical intestinal inflammation in ankylosing spondylitis. Arthritis Rheum 2009; 60:955-965.
33. McGovern D, Powrie F. The IL23 axis plays a key role in the pathogenesis of IBD. Gut 2007; 56:1333-1336. (Pubitemid 47517817)
34. Appel H, Maier R, Wu P, et al. Analysis of IL-17[+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther 2011; 13:R95.
35. Noordenbos T, Yeremenko N, Gofita I, et al. Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum 2012; 64:99-109.
36. Appel H, Maier R, Bleil J, et al. In situ analysis of interleukin-23-and interleukin-12-positive cells in the spine of patients with ankylosing spondylitis. Arthritis Rheum 2013; 65:1522-1529.
37. Hreggvidsdottir HS, Noordenbos T, Baeten DL. Inflammatory pathways in spondyloarthritis. Molec Immunol 2014; 57:28-37.
38. Uhlig HH, McKenzie BS, Hue S, et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity 2006; 25:309-318.
39. Colbert RA, Tran TM, Layh-Schmitt G. HLA-B27 misfolding and ankylosing spondylitis. Molec Immunol 2014; 57:44-51.
40. Ciccia F, Accardo-Palumbo A, Rizzo A, et al. Evidence that autophagy, but not the unfolded protein response, regulates the expression of IL-23 in the gut of patients with ankylosing spondylitis and subclinical gut inflammation. Ann Rheum Dis 2013; 10.1136/annrheumdis-2012-202925. [Epub ahead of print]
41. Rich P, Sigurgeirsson B, Thaci D, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Derma-tol 2013; 168:402-411.
42. McInnes IB, Sieper J, Braun J, et al. Efficacy and safety of secukinumab, a fully human antiinterleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 2014; 73:349-356.
43. Baeten D, Baraliakos X, Braun J, et al. Antiinterleukin-17A monoclonal anti-body secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 2013; 382:1705-1713.
44. Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012; 61:1693-1700.
45. Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional nonbiological and biological antitumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014; 10.1136/annrheumdis-2013-204655. [Epub ahead of print]
46. Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and main tenance therapy in refractory Crohn's disease. N Engl J Med 2012; 367:1519-1528.
47. Poddubnyy D, Callhoff J, Listing J, Sieper J. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Arthritis Rheum 2013; 65:S766-S770.